Hepatitis C virus infection among transmission-prone medical personnel

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1473-7. doi: 10.1007/s10096-011-1466-9. Epub 2011 Nov 3.

Abstract

Hepatitis C virus (HCV)-infected physicians have been reported to infect some of their patients during exposure-prone procedures (EPPs). There is no European consensus on the policy for the prevention of this transmission. To help define an appropriate preventive policy, we determined the prevalence of HCV infection among EPP-performing medical personnel in the Academic Medical Center in Amsterdam, the Netherlands. The prevalence of HCV infection was studied among 729 EPP-performing health care workers. Serum samples, stored after post-hepatitis B virus (HBV) vaccination testing in the years 2000-2009, were tested for HCV antibodies. Repeat reactive samples were confirmed by immunoblot assay and the detection of HCV RNA. The average age of the 729 health care workers was 39 years (range 18-66), suggesting a considerable cumulative occupational exposure to the blood. Nevertheless, only one of the 729 workers (0.14%; 95% confidence interval [CI]: <0.01% to 0.85%) was tested and confirmed to be positive for anti-HCV and positive for HCV RNA, which is comparable to the prevalence of HCV among Amsterdam citizens. Against this background, for the protection of personnel and patients, careful follow-up after needlestick injuries may be sufficient. If a zero-risk approach is desirable and costs are less relevant, the recurrent screening of EPP-performing personnel for HCV is superior to the follow-up of reported occupational exposures.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Health Personnel*
  • Hepatitis C / epidemiology*
  • Hepatitis C / prevention & control*
  • Hepatitis C / transmission
  • Hepatitis C Antibodies / blood
  • Humans
  • Immunoblotting
  • Infectious Disease Transmission, Professional-to-Patient / prevention & control
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Prevalence
  • RNA, Viral / blood
  • Risk Assessment
  • Young Adult

Substances

  • Hepatitis C Antibodies
  • RNA, Viral